Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.72 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.72 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.55 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19606405 | 0.95 | CRBN (0.65) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL30993171 | 0.95 | CRBN (0.65) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL27347266 | 0.95 | CRBN (0.65) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL27347653 | 0.94 | CRBN (0.64) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL27347502 | 0.94 | CRBN (0.64) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL26835997 | 0.94 | CRBN (0.64) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL22289929 | 0.94 | CRBN (0.64) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL21106602 | 0.93 | STAT3 (0.68) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL29612686 | 0.93 | STAT3 (0.68) | CRBNDDB1STAT3MAP1LC3BBRD4 | |
| SCHEMBL26815430 | 0.92 | STAT3 (0.65) | CRBNDDB1STAT3MAP1LC3BBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | CRBN 97/4885DDB1 940/4885STAT3 601/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885STAT3 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.